BRNS

MKT CAP:$25M

Barinthus Biotherapeutics plc

Market Cap

$25M

Healthcare·Biotechnology·🇬🇧 United Kingdom·NASDAQ

Healthcare·Biotechnology·🇬🇧·NASDAQ

Stock Price

$0.64-$0.10 (-13.06%)

Apr 23, 2026

Company Details

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a...

CEO

William James Enright

IPO Date

Apr 30, 2021

Website

www.barinthusbio.com

Key Metrics TTM

Revenue

$0

-100.0% YoY

Net Income

-$66M

EPS (Diluted)

-$1.64

Free Cash Flow

-$48M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 6, 2026

PENDING

FY 2025

Mar 13, 2026

$0-100.0%EPS -$1.64

Q4 2025

Mar 13, 2026

$0EPS -$0.27

Q3 2025

Nov 7, 2025

$0-100.0%EPS -$0.36

Q2 2025

Aug 7, 2025

$0EPS -$0.52

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	-$1.0K	-$7M	-$17M
Q2 22	$17M	$7M	$13M
Q3 22	$6M	-$4M	$7M
Q4 22	$6M	-$6M	-$25M
Q1 23	$468.0K	-$9M	-$21M
Q2 23	$334.0K	$334.0K	-$26M
Q3 23	$0	$0	-$16M
Q4 23	$0	$0	-$20M
Q1 24	$0	$0	-$17M
Q2 24	$0	$0	-$18M
Q3 24	$15M	$15M	-$9M
Q4 24	$0	$0	-$23M
Q1 25	$0	$0	-$21M
Q2 25	$0	$0	-$23M
Q3 25	$0	$0	-$15M
Q4 25	$0	-$907.7K	$5M

Valuation

Quarter	P/S	P/E
Q4 21	61.3x	—
Q2 22	1.5x	—
Q3 22	1.1x	5.9x
Q4 22	0.8x	—
Q1 23	0.8x	—
Q2 23	1.9x	—
Q3 23	3.4x	—
Q4 23	31.1x	—
Q1 24	74.7x	—
Q2 24	—	—
Q3 24	1.7x	—
Q4 24	1.7x	—
Q1 25	1.7x	—
Q2 25	1.7x	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$8M	-$8M
Q2 22	-$8M	-$10M
Q3 22	$12M	$9M
Q4 22	-$11M	-$12M
Q1 23	-$3M	-$6M
Q2 23	-$17M	-$20M
Q3 23	-$11M	-$11M
Q4 23	-$20M	-$19M
Q1 24	-$12M	-$12M
Q2 24	-$12M	-$12M
Q3 24	-$18M	-$18M
Q4 24	$13M	$13M
Q1 25	-$15M	-$15M
Q2 25	-$18M	-$18M
Q3 25	-$11M	-$11M
Q4 25	-$4M	-$4M

Capital Expenditures

Quarter	CapEx
Q4 21	$424.0K
Q2 22	$2M
Q3 22	$2M
Q4 22	$586.0K
Q1 23	$3M
Q2 23	$3M
Q3 23	$36.0K
Q4 23	$153.0K
Q1 24	$308.0K
Q2 24	$192.0K
Q3 24	$114.0K
Q4 24	$278.0K
Q1 25	$5.0K
Q2 25	$32.0K
Q3 25	$0
Q4 25	$50

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 22	+4720.1%	-61.7%
Q3 22	+17514.3%	-106.3%
Q4 22	+33884.2%	+468.0%
Q1 23	+46900.0%	+31.7%
Q2 23	-98.0%	+596.7%
Q3 23	-100.0%	+1603.7%
Q4 23	-100.0%	-36.6%
Q1 24	-100.0%	-23.0%
Q2 24	-100.0%	-31.4%
Q3 24	—	+51.2%
Q4 24	—	+17.0%
Q1 25	—	+21.8%
Q2 25	—	+27.6%
Q3 25	-100.0%	-38.1%
Q4 25	—	-120.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$4M	—
Q2 22	$3M	16.1%
Q3 22	$1M	17.9%
Q4 22	$2M	31.6%
Q1 23	$2M	474.8%
Q2 23	$2M	595.8%
Q3 23	$57.0K	—
Q4 23	$786.0K	—
Q1 24	$2M	—
Q2 24	$1M	—
Q3 24	$1M	7.6%
Q4 24	$755.0K	—
Q1 25	$468.0K	—
Q2 25	-$281.0K	—
Q3 25	-$415.0K	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 21	$7M	$10M	—
Q2 22	$11M	$7M	—
Q3 22	$11M	$11M	—
Q4 22	$13M	$20M	—
Q1 23	$11M	$12M	$431.0K
Q2 23	$13M	$13M	—
Q3 23	$14M	$961.0K	—
Q4 23	$6M	$14M	—
Q1 24	$11M	$6M	—
Q2 24	$11M	$7M	—
Q3 24	$11M	$13M	—
Q4 24	$6M	$3M	—
Q1 25	$8M	$13M	—
Q2 25	$7M	$15M	—
Q3 25	$5M	$5M	—
Q4 25	$4M	$8M	—

Revenue Segments

Quarter	License
Q3 24	$15M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$201M	$0	$201M
Q2 22	$192M	$0	$192M
Q3 22	$200M	$0	$200M
Q4 22	$194M	$0	$194M
Q1 23	$191M	$0	$191M
Q2 23	$173M	$0	$173M
Q3 23	$160M	$0	$160M
Q4 23	$142M	$0	$142M
Q1 24	$130M	$0	$130M
Q2 24	$118M	$0	$118M
Q3 24	$106M	$0	$106M
Q4 24	$111M	$0	$111M
Q1 25	$99M	$0	$99M
Q2 25	$86M	$0	$86M
Q3 25	$74M	$0	$74M
Q4 25	$70M	$0	$70M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	37M	+6.7%	—
Q2 22	38M	+2.6%	+379.7%
Q3 22	38M	-0.0%	+53.3%
Q4 22	38M	-1.2%	+8.2%
Q1 23	38M	+0.9%	+2.2%
Q2 23	38M	+1.0%	+0.6%
Q3 23	39M	+0.3%	+1.0%
Q4 23	39M	+0.2%	+2.4%
Q1 24	39M	+0.4%	+2.0%
Q2 24	39M	+0.7%	+1.6%
Q3 24	39M	+1.0%	+2.3%
Q4 24	39M	-0.2%	+1.9%
Q1 25	40M	+2.3%	+3.8%
Q2 25	40M	+0.2%	+3.3%
Q3 25	41M	+0.8%	+3.2%
Q4 25	41M	-0.3%	+3.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	$0	130
Q1 24	$0	130
Q2 24	$0	130
Q3 24	$115.1K	130
Q4 24	$0	105
Q1 25	$0	105
Q2 25	$0	105
Q3 25	$0	105
Q4 25	$0	200K

Revenue / Employee